BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, Cheon JH, Im JP, Kim YS. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:35-44. [PMID: 26395533 DOI: 10.1586/17474124.2015.1091309] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 13.5] [Reference Citation Analysis]
2 Mignogna MD, Leuci S. Interface Between Oral and Systemic Disease. In: Farah CS, Balasubramaniam R, Mccullough MJ, editors. Contemporary Oral Medicine. Cham: Springer International Publishing; 2019. pp. 67-136. [DOI: 10.1007/978-3-319-72303-7_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Lee YM, Kang B, Lee Y, Kim MJ, Choe YH. Infliximab “Top-Down” Strategy is Superior to “Step-Up” in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2015;60:737-43. [DOI: 10.1097/mpg.0000000000000711] [Cited by in Crossref: 34] [Cited by in F6Publishing: 14] [Article Influence: 4.9] [Reference Citation Analysis]
4 Zhang T, Lin QY, Fei JX, Zhang Y, Lin MY, Jiang SH, Wang P, Chen Y. Clostridium Difficile Infection Worsen Outcome of Hospitalized Patients with Inflammatory Bowel Disease. Sci Rep 2016;6:29791. [PMID: 27417996 DOI: 10.1038/srep29791] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
5 Abbass M, Cepek J, Parker CE, Nguyen TM, MacDonald JK, Feagan BG, Khanna R, Jairath V. Adalimumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2019;2019. [PMID: 31742665 DOI: 10.1002/14651858.CD012878.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Freeman HJ. Natural history and long-term clinical course of Crohn’s disease. World J Gastroenterol 2014; 20(1): 31-36 [PMID: 24415855 DOI: 10.3748/wjg.v20.i1.31] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 56] [Article Influence: 8.5] [Reference Citation Analysis]
7 Brown I, Kumarasinghe MP. Granulomas in the gastrointestinal tract: deciphering the Pandora's box. Virchows Arch 2018;472:3-14. [PMID: 28776106 DOI: 10.1007/s00428-017-2210-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
8 D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG; Laquinimod for Crohn's Disease Investigators. A phase II study of laquinimod in Crohn's disease. Gut 2015;64:1227-35. [PMID: 25281416 DOI: 10.1136/gutjnl-2014-307118] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 7.6] [Reference Citation Analysis]
9 Speciale A, Muscarà C, Molonia MS, Toscano G, Cimino F, Saija A. In Vitro Protective Effects of a Standardized Extract From Cynara Cardunculus L. Leaves Against TNF-α-Induced Intestinal Inflammation. Front Pharmacol 2022;13:809938. [DOI: 10.3389/fphar.2022.809938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Echarri A, Ollero V, Barreiro-de Acosta M, Fernández-villaverde A, Hernández V, Lorenzo A, Pereira S, Carpio D, Castro J. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease: predictors of efficacy in clinical practice. European Journal of Gastroenterology & Hepatology 2015;27:430-5. [DOI: 10.1097/meg.0000000000000296] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
11 Asgharpour A, Cheng J, Bickston SJ. Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clin Exp Gastroenterol 2013;6:153-60. [PMID: 24039442 DOI: 10.2147/CEG.S35163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
12 Rammohan H, Pai CG. Shrinking Indications for Azathioprine in Crohn's Disease: A Conclusion too Premature? Gastroenterology 2014;146:866-7. [DOI: 10.1053/j.gastro.2013.10.071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Graf D, Monk JM, Wu W, Wellings HR, Robinson LE, Power KA. Red lentil supplementation reduces the severity of dextran sodium sulfate-induced colitis in C57BL/6 male mice. Journal of Functional Foods 2020;64:103625. [DOI: 10.1016/j.jff.2019.103625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Bezerra-filho CS, Barboza JN, Souza MT, Sabry P, Ismail NS, de Sousa DP. Therapeutic Potential of Vanillin and its Main Metabolites to Regulate the Inflammatory Response and Oxidative Stress. MRMC 2019;19:1681-93. [DOI: 10.2174/1389557519666190312164355] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
15 Yu Y, Song EM, Lee KE, Joo YH, Kim SE, Moon CM, Kim HY, Jung SA, Jo I. Therapeutic potential of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced experimental murine colitis. PLoS One 2017;12:e0183141. [PMID: 28854223 DOI: 10.1371/journal.pone.0183141] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
16 Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113-120. [PMID: 25075198 DOI: 10.2147/jir.s65979] [Cited by in Crossref: 172] [Cited by in F6Publishing: 83] [Article Influence: 21.5] [Reference Citation Analysis]
17 Shin JS, Kim JS, Kim JM, Jang JY, Kim YH, Kim HJ, Park CG. Minimizing immunosuppression in islet xenotransplantation. Immunotherapy 2014;6:419-30. [PMID: 24815782 DOI: 10.2217/imt.14.14] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
18 Song JH, Hong SN, Lee JE, Kim K, Kim TJ, Kim ER, Chang DK, Kim YH. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease. Scand J Gastroenterol 2019;54:876-85. [PMID: 31303093 DOI: 10.1080/00365521.2019.1638962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Freeman HJ. Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab. Ther Clin Risk Manag. 2013;9:451-456. [PMID: 24235838 DOI: 10.2147/TCRM.S38852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
20 Sager R, Frei P, Steiner UC, Fink D, Betschart C. Genital Dysplasia and Immunosuppression: Why Organ-Specific Therapy Is Important. Inflamm Intest Dis 2019;4:154-60. [PMID: 31768388 DOI: 10.1159/000502687] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Awad AS, You H, Gao T, Cooper TK, Nedospasov SA, Vacher J, Wilkinson PF, Farrell FX, Brian Reeves W. Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury. Kidney Int 2015;88:722-33. [PMID: 26061548 DOI: 10.1038/ki.2015.162] [Cited by in Crossref: 96] [Cited by in F6Publishing: 92] [Article Influence: 13.7] [Reference Citation Analysis]
22 Marzano AV, Borghi A, Meroni PL, Crosti C, Cugno M. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity 2014;47:146-53. [PMID: 24437626 DOI: 10.3109/08916934.2013.873414] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]